Intensity Therapeutics, Inc. (INTS) stock
INTSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$3.28+0.19 (+6.15%)
Close on Nov 11, 2026Market cap $10.71MP/E –Yield –
Intensity Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Intensity Therapeutics's R&D Expenses for the twelve months ending Sep 30, 2026 was $6.96M, down 4.0% year over year. For fiscal 2025 it was $6.79M, down 35.4% from the year before.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.79M | -35.4% |
| FY2024 | Dec 31, 2024 | $10.50M | +119.3% |
| FY2023 | Dec 31, 2023 | $4.79M | -6.7% |
| FY2022 | Dec 31, 2022 | $5.13M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $2.43M | +56.4% |
| Q2 FY2026 | Jun 30, 2026 | $1.83M | +18.9% |
| Q1 FY2026 | Mar 31, 2026 | $1.20M | -45.4% |
| Q4 FY2025 | Dec 31, 2025 | $1.50M | -23.6% |
| Q3 FY2025 | Sep 30, 2025 | $1.55M | -27.8% |
| Q2 FY2025 | Jun 30, 2025 | $1.54M | -56.7% |
| Q1 FY2025 | Mar 31, 2025 | $2.19M | -22.2% |
| Q4 FY2024 | Dec 31, 2024 | $1.97M | +9.2% |
| Q3 FY2024 | Sep 30, 2024 | $2.15M | +59.1% |
| Q2 FY2024 | Jun 30, 2024 | $3.56M | +314.8% |
| Q1 FY2024 | Mar 31, 2024 | $2.82M | +263.7% |
| Q4 FY2023 | Dec 31, 2023 | $1.80M | +102.2% |
| Q3 FY2023 | Sep 30, 2023 | $1.35M | +16.5% |
| Q2 FY2023 | Jun 30, 2023 | $859.00K | -38.0% |
| Q1 FY2023 | Mar 31, 2023 | $774.00K | – |
| Q4 FY2022 | Dec 31, 2022 | $890.80K | – |
| Q3 FY2022 | Sep 30, 2022 | $1.16M | – |
| Q2 FY2022 | Jun 30, 2022 | $1.39M | – |
See a number that looks wrong?